MAY 10, 2018 01:49 PM PDT

New Biomarker for Lung Cancer Diagnosis

WRITTEN BY: Kara Marker
3 2 321

Lung cancer is the most common cause of death from cancer for both genders and for people all over the globe. This is largely due to the lack of diagnostic markers that indicate early stages of cancer. But now, scientists from a new Japan study introduce a biomarker that could drastically change cancer diagnostics and treatment: CKAP4.

Histopathology of small cell lung carcinoma. Credit: Yale Rosen

There are several existing biomarkers that scientists use to diagnose lung cancer:

  • Carcinoma embryonic antigen (CEA)
  • Sialyl Lewis X antigen (SLX)
  • Squamous cell carcinoma (SCC) antigen
  • Cytokeratin fragment (CYFRA) 21-1

But none of them are sensitive enough to detect lung cancer in its early stages, and this is a huge problem for diagnosis, prognosis, and treatment of patients affected.

In the new study, researchers used several lab techniques to test a monoclonal antibody called KU-Lu-1. A monoclonal antibody is a lab-derived protein that binds to other proteins in the body. In this case, KU-Lu-1 only targeted tumor cells from lung cancer tissues, not normal lung tissues. Researchers first tested KU-Lu-1 in blood samples from 271 different lung cancer patients and 100 healthy individuals.

After confirming that KU-Lu-1 only targeted cancerous tissue, researchers observed that KU-Lu-1 targets lung cancer cells by recognizing cytoskeleton-associated protein 4 (CKAP4).

"The results of our study provide evidence that the CKAP4 protein may be a novel early sero-diagnostic marker for lung cancer,” explained co-investigator Ryo Nagashio, PhD.

"The use of CKAP4 as a biomarker could change current practices regarding the treatment of lung cancer patients, and the diagnostic accuracies may be markedly improved by the combination of CKAP4 and conventional markers," explained study leader Yuichi Sato, PhD.

CKAP4 is a receptor of another protein called Dickkopf1 (DKK1). When both of these proteins are expressed, prognosis worsens and the chance of relapse-free survival for lung cancer patients minimizes.

"The identification of patients at an early stage of cancer when it can be treated surgically is extremely important to improve prognosis," Sato concluded. "We need better biomarkers for early diagnosis."

The present study was published in the American Journal of Pathology.

Sources: Elsevier, National Cancer Institute

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 09, 2018
Immunology
APR 09, 2018
Unique Molecular Interactions Dictate B Cell Tolerance
An important cellular reaction mediates part of the immune system responsible for tolerance. Without tolerance, the immune system would target harmless &ld
APR 19, 2018
Immunology
APR 19, 2018
New Treatment for Psoriasis and Other Autoimmune Diseases
The same compound that helps immune cells detect bacteria during an invasion could help scientists design a new drug to treat psoriasis, an autoimmune dise
APR 28, 2018
Cardiology
APR 28, 2018
Eating Dark Chocolate Reduces Stress, Improves Mood
We’ve heard that dark chocolate is good for us in reasonable amounts, but two unique studies from the Loma Linda University Adventist Health Sciences
JUN 13, 2018
Health & Medicine
JUN 13, 2018
Insurance Denials Prevent Patients From Getting Hep C Medication
Some ads are running on television and in major magazines about drugs for hepatitis C, known as Hep C or HCV. Available in the United States since 2014, th
JUN 22, 2018
Health & Medicine
JUN 22, 2018
A New Test for Peanut Allergy: Better, Faster, Cheaper.
Scientists from the Medical Research Council (MRC) in the UK have come up with a test to detect peanut allergies and it’s safer, quicker and more acc
JUN 30, 2018
Immunology
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point
Loading Comments...